噻托溴铵和舒利迭联合治疗中重度慢性阻塞性肺疾病的疗效观察

目的探讨噻托溴铵和舒利迭联用对中重度慢性阻塞性肺疾病(COPD)患者的疗效观察。方法收集中重度稳定期型COPD患者50例,按照治疗方法的不同,分为观察组和对照组,观察组采用噻托溴铵和舒利迭联用治疗,对照组采用舒利迭进行治疗,对两组患者的肺功能及6 min步行试验(6MWD)和呼吸困难量表(MMRC)评分进行比较。结果治疗后3个月,观察组的肺功能一秒钟用力呼气容积(FEV1)、最大肺活量(FVC)、FEV1/FCV(%)和FEV1%的预测值高于对照组,差异有统计学意义(P<0.05);观察组MMRC、6MWT评分亦高于对照组,差异有统计学意义(P<0.05)。结论噻托溴铵与舒利迭联合应用治疗COPD明显优于单药舒利迭治疗,值得临床推广。

STUDY ON Curative effect of thiamethoxan bromide and seretide in treatment of patients with moderately severe COPD

Objective To explore the curative effect of thiamethoxam bromide and Seretide in treatment of patients with COPD.Methods Fifety patients with moderately severe COPD were collected,according to different methods of treatment,they were divided into observation group and control group,patients in observation group were given with thiamethoxam bromide and Seretide for treatment,patients in control group were only received Seretide for treatment,and lung function,6 MWT and MMRC scores of patients in these two groups were compared.Results After treatment for 3 months,the predicted values of lung function FEV1（L）,FCV（L）,FEV1 / FCV（%） and FEV1 % were compared between these 2 groups,and the difference was statistically significant（P 0.05）;MMRC and 6 MWT scores were compared between observation group and control group,the difference was statistically significant（P 0.05）.Conclusion The treatment of patients with moderately severe COPD by thiamethoxam bromide and Seretide is superior to monotherapy.It is worthy for clinical popularization and application.